Aratana Therapeutics Inc (NASDAQ:PETX) Receives Average Recommendation of “Hold” from Analysts

Aratana Therapeutics Inc (NASDAQ:PETX) has received a consensus rating of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $4.73.

A number of brokerages recently weighed in on PETX. Credit Suisse Group upgraded shares of ConocoPhillips from a “neutral” rating to an “outperform” rating and set a $75.00 price objective for the company in a report on Tuesday, April 30th. BidaskClub upgraded shares of Zebra Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 6th. Zacks Investment Research lowered shares of ExlService from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th. Finally, HC Wainwright restated a “buy” rating on shares of Oragenics in a report on Friday, April 26th.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Aratana Therapeutics by 5.5% in the 4th quarter. BlackRock Inc. now owns 3,629,595 shares of the biopharmaceutical company’s stock valued at $22,249,000 after purchasing an additional 190,011 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Aratana Therapeutics by 10.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,233,219 shares of the biopharmaceutical company’s stock valued at $7,559,000 after purchasing an additional 114,383 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Aratana Therapeutics by 116.7% in the 4th quarter. Millennium Management LLC now owns 642,923 shares of the biopharmaceutical company’s stock valued at $3,941,000 after purchasing an additional 346,243 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Aratana Therapeutics by 21.2% in the 4th quarter. Geode Capital Management LLC now owns 526,329 shares of the biopharmaceutical company’s stock valued at $3,226,000 after purchasing an additional 91,968 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Aratana Therapeutics by 1.6% in the 4th quarter. Northern Trust Corp now owns 515,994 shares of the biopharmaceutical company’s stock valued at $3,163,000 after purchasing an additional 8,135 shares in the last quarter. Institutional investors and hedge funds own 65.00% of the company’s stock.

PETX traded down $0.13 on Tuesday, reaching $4.93. 3,040,300 shares of the company traded hands, compared to its average volume of 799,614. Aratana Therapeutics has a one year low of $3.30 and a one year high of $7.16. The firm has a fifty day moving average price of $4.95. The firm has a market capitalization of $247.05 million, a P/E ratio of -15.41 and a beta of 1.40.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). Aratana Therapeutics had a negative net margin of 33.47% and a negative return on equity of 12.99%. The company had revenue of $7.36 million for the quarter, compared to the consensus estimate of $6.98 million. Equities research analysts expect that Aratana Therapeutics will post -0.31 earnings per share for the current year.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States.

Further Reading: Death Cross

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.